AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06248463 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: BP measurement in waiting room for 20 minutes
Description: Measured of BP will be performance in waiting room for 20 minutes every 3 minutes and report by an mobile app. After 24h-ABPM device will be implanted. Results of SBP and DBP obtained in office will be compared with 24-h, diurnal and nocturnal SBP/DBP mean.~BP will be measured automatically and repeatedly every 3 minutes in the waiting room for 20 minutes. Subsequently, a SpaceLab ABPM monitor will be implanted.
Study NCT05621018 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Maze Out
Description: Play for 15 weeks, at list once a week the serious game: Maze Out
Study NCT06266572 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Overcoming and Addressing Stigma in Substance Use Disorders (OASIS)
Description: Web-based educational platform for clinicians and individuals with OUD that will decrease barriers to care and enhance treatment outcomes
Study NCT06497621 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single step PVS impression
Description: Single-step final impression method for complete denture fabrication using medium body PVS for border molding and wash impression in a single-step (i.e., one insertion of impression tray in mouth).
Study NCT06497621 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional two-step PVS impression
Description: Border molding with heavy-body PVS first, followed by wash impression with light-body PVS
Study NCT06025084 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Egg Shell nanoparticles
Description: Evaluate the effects of egg shell nanoparticles combined with Titanium dioxide nanoparticles in the treatment of dentin hypersensitivity at different time intervals.
Study NCT04933409 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 3D printed replica of the donor tooth
Description: 3D printed replica of the donor tooth.
Study NCT04933409 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Autotransplantation of tooth
Description: Conventional Autotransplantation of tooth without using the 3D printed guide
Study NCT06162871 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Presentations and interactive debate sessions, with intergenerational exchange
Description: Intervention will consist of 12 sessions, each lasting about two hours, conducted on a weekly basis and delivered both in-person and remotely. The sessions will include presentations and interactive debate sessions, with a central focus on intergenerational exchange covering cultural, historical, and health-related topics. A key aspect is the active involvement of beneficiaries, individuals over sixty-five, who will be asked to prepare presentations with the support of project-provided facilitators. Simultaneously, the project will promote and enhance skills, organizational capabilities, and computer literacy.
Study NCT05615038 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Contact aspiration Thrombectomy
Description: Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.
Study NCT05615038 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Stent retriever thrombectomy
Description: Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.
Study NCT05578196 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fecal bacteria solution
Description: The gastrointestinal tube access was established, and the standard preparation of fecal bacteria solution 20ml (frozen at -80 ° C, melted at room temperature before use) was injected through the gastrointestinal tube once a day for 6 consecutive days. The other treatment measures were the same as those of the control group.
Study NCT05578196 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: physiological saline solution
Description: physiological saline solution 20ml
Study NCT05223699 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MGTA-117
Description: MGTA-117 will be administered as an IV infusion
Study NCT05057325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpectomy using single file system ( One Shape file)
Description: Rotary file instrument for pulpectomy of primary molars ( One shape file)
Study NCT05057325 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pulpectomy using single file system ( WaveOne Gold file)
Description: Rotary file instrument for pulpectomy of primary molars ( WaveOne Gold file)
Study NCT05525039 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-magnitude High-frequency Vibration
Description: 0.3g, 35Hz, 20mins/day, at least 3 times/week
Study NCT05525039 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Low-magnitude High-frequency Vibration
Description: 0.3g, 35Hz, 20mins/day, at least 3 times/week
Study NCT05525039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: β-hydroxy β-methylbutyrate (HMB) supplement
Description: Oral nutritional HMB supplement at 3g/day
Study NCT05525039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: β-hydroxy β-methylbutyrate (HMB) supplement
Description: Oral nutritional HMB supplement at 3g/day
Study NCT05525039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Protein supplement
Description: Daily protein supplement intake
Study NCT05525039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Protein supplement
Description: Daily protein supplement intake
Study NCT05525039 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein supplement
Description: Daily protein supplement intake
Study NCT05743127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 3D-Printed Hyrax Expander
Description: This is a type of maxillary expander that is designed on a computer and printed in metal using 3D printers and is used to expand the upper jaw.
Study NCT05743127 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Conventional Laboratory Fabricated Hyrax Expander
Description: This is a type of maxillary expander that is made by hand in an orthodontic laboratory and is used to expand the upper jaw.
Study NCT04976790 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Chinese Tuina therapy
Description: Firstly, the patient is in the prone position, and the doctor use the method of rolling or kneading the Bladder meridians on both sides of the spine. The waist will be focused on to manipulate preferentially and then using the same technique on the patient's back, buttocks and lower limbs. Secondly, the physician will perform the manipulation on the patient's waist and the posterolateral side of the lower limbs by pressing, kneading, plucking. The doctors press the acupoints, including Mingmen(DU04),Shenshu(BL23),Yaoyangguan(DU03),Huantiao(GB30), Weizhong(BL40),Chengshan(BL57),and Ashi points, with the elbow or the thumb to achieve Deqi sensation. Thirdly, the The doctor uses the method of pressing acupoints, including Tianshu(ST25),Qichong(ST30),Chongmen(SP12),Daimai(GB26),Jingmen(GB25) on both sides. Fourthly, the patient is required to face the doctor in a lateral position for pulling manipulation on the both sides of lumbar vertebrae.
Study NCT04976790 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Flurbiprofen Cataplasms group (FCG).
Description: One Flurbiprofen Cataplasm was applied to the left and right sides of the waist, twice daily, for 14 days
Study NCT06527261 — intervention group
Intervention type: OTHER
Intervention: Real-time electronic data input into REDCap
Description: During usual care sessions, clinicians will real-time capture information about the intervention session into REDCap. This information is related to the multi-dimensional dose articulation framework e.g., content of the session and difficulty of the task, session length, episode length, and number of repetitions.~The usual care motor upper limb intervention the patient receives is determined by the clinician providing the care. The therapy may include but is not limited to strength training, task specific retraining, constraint induced movement therapy, mirror box, and electrical stimulation.
Study NCT06368843 — intervention group
Intervention type: DRUG
Intervention: Gargle with ketamine
Description: The patients asked to gargling with ketamine solution in the preoperative waiting area after explain the whole procedure and the goals of the study.
Study NCT05618210 — intervention group
Intervention type: OTHER
Intervention: regional anesthesia
Description: in the ESPB group, the linear ultrasound probe was placed in the erector spina muscles were visualized on the side where VATS was planned. block needle can be seen on ultrasound, the skin and erector spina muscles are passed in the cranio-caudal direction. ESPB will be administered with 20 ml of 0.5% bupivacaine by visualizing the local anesthetic spread linearly.~In the rhomboid intercostal block group, the ipsilateral arm is positioned towards the chest, allowing the scapula to move laterally and the area called auscultation triangle to be opened, and after the skin disinfection of the surgical side; By using a linear ultrasound probe, the rhomboid major and intercostal muscles will be defined in the auscultation triangle region, and T5-6 level with an in-plane approach with 20 ml of 0.5% bupivacaine and local anesthetic injection.
Study NCT04841785 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: mailer-based finger-prick
Description: All participants in the antibody measurement study will be sent a mailer-based finger-prick set. The sets will be sent to the home address of the patient, including a return envelope. After collecting and returning the samples SARS-CoV-2 antibodies will be analysed quantitatively at the laboratory.
Study NCT06471699 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Continous Glucose Monitoring
Description: The aim is to examine if the use of CGM will give the participants a significant support to implement lifestyle improvements in individuals with new on-set type 2 diabetes
Study NCT06471699 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Self monitoring blood glucose
Description: Capillary testing as in standard procedure
Study NCT05063617 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SCI Step Together
Description: The 8-week program features weekly blocks of content. Each week builds from the previous week and targets specific components related to the three basic psychological needs (autonomy, relatedness, competence). The overall cadence of each weekly block is maintained throughout. For example, each week contains: 1) education modules 2) a worksheet or guided practice to apply the strategies in their own goals for that week along with embedded questions to discuss with their community coach 3) behavioural support from the community coach and 4) peer support from the discussion group.
Study NCT05979155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NWY001
Description: Part 1: Participants will be given a single-dose of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
Study NCT05644600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nintedanib
Description: The subjects will be administered Nintedanib soft capsules single oral dose in the morning of Day 1 in fasted state.
Study NCT05644600 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD5055
Description: The subjects will be administered AZD5055 as single oral dose on Day 1 in the fasted state.
Study NCT05979155 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: NWY001
Description: Part 2: Participants will be given RP2D of NWY001 intravenously once every 3 weeks until a discontinuation criteria was met during treatment period.
Study NCT05074862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: KetoneAid KE4 Pro Monoester
Description: A dietary supplement containing ketone monoester.
Study NCT05074862 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Maltodextrin and fat-based placebo
Description: Dosis isocaloric to the KetoneAid Arm
Study NCT06332040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gentamicin
Description: random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
Study NCT06332040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Gentamicin
Description: random assignment to gentamicin or placebo bladder instillation to prevent CAUTI (catheterized urinary track infection)
Study NCT06221956 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: relevis
Description: Participants will receive access to the digital health intervention relevis in addition to TAU.
Study NCT05256316 — intervention group
Intervention type: OTHER
Intervention: Previously admitted COVID-19 patients in intensive care units
Description: Exposure: this is a retrospective, observational study that does not include an intervention. Data collected for this study will be from previously hospitalized COVID-19 patients who had an intensive care unit stay during their admission
Study NCT04297345 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hemodialysis
Description: Blood enters the extracorporeal circuit from the arterial line of the femoral catheter. For this the investigators use a pump integrated in the monitor, equipped with control systems, exerting a negative pressure.~Subsequently, it enters the dialyzer through the internal part of the capillaries (porous), producing a passive exchange of inflammatory and oxidative substances (such as cytokines) with the dialysis fluid, which also circulates through the dialyzer, but through the external part of the capillaries. Blood is returned to the patient, through the venous line of the catheter, with a lower concentration of cytokines after passing through the dialyzer.~This circuit is repeated continuously during the 3 hours of the procedure to ensure maximum clearance of glutamate and interleukins, among other substances.
Study NCT06196619 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: SWE:B-mode ultrasound and subcutaneous elastic modulus with shear wave elastography at three level
Description: Visual analog scale(VAS):This scale measure in which individuals rate their pain from 0 to 10, with 0 indicating no pain at all and 10 representing the worst pain;pain threshold through algometric measurement; quality of life using the EQ-5D general quality of life scale.
Study NCT05116891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CAN04 (nadunolimab)
Description: FULLY HUMANISED MONOCLONAL ANTIBODY AGAINST IL1RAP
Study NCT05116891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: mFOLFOX
Description: mFOLFOX/CAN04
Study NCT05116891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DTX
Description: DTX/CAN04
Study NCT05116891 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G/C
Description: G/C/CAN04
Study NCT04914767 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nigella
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.
Study NCT04914767 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The patient will receive a study treatment containing 100 capsules:~* One capsule every two hours for the first three days.~* From the fourth day, the patient will take one capsule, three times a day for 12 days.
Study NCT05351905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CBD oil ( MPL-001)
Description: MPL-001: which is a 25:1 Cannabidiol (CBD): ∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 50 mg/ml of CBD and 2 mg/ml of THC. The starting dose will be 1 mL per day (50 mg CBD) orally and gradually titrated to a maximum dose of 6 mL (300 mg CBD) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Study NCT05351905 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CDB+THC oil (MPL-005)
Description: MPL-005: which is a 5:1 Cannabidiol (CBD):∆9-tetrahydrocannabidiol (THC) oral formulation with a concentration of 25 mg/ml of CBD and 5 mg/ml of THC. The starting dose will be 1 mL per day (25 mg CBD + 5 mg THC) orally and gradually titrated to a maximum dose of 6 mL (150 mg CBD + 30 mg THC) per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Study NCT05351905 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oil
Description: The starting dose will be 1 mL per day (contains no API) orally and gradually titrated to a maximum dose of 6 mL per day in a divided dosage within 6 to 8 weeks of treatment initiation based on patient assessment. Once the optimal dose has been determined, which maximizes potential therapeutic effects while minimizing adverse effects, the dose will be maintained for the remainder of the trial.
Study NCT05976568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QL1706
Description: 7.5 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
Study NCT05976568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
Study NCT05976568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bevacizumab
Description: 15 mg/kg administered as IV infusion on Day 1 of each 21-day cycle
Study NCT05976568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin injection
Description: 85 mg/m2 administered as IV infusion on Day 1 of each 21-day cycle
Study NCT05976568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: 1000 mg/m2 orally twice daily for 14 days continuous dosing followed by a 7-day break of each 21-day cycle
Study NCT05976568 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sintilimab
Description: 200 mg administered as IV infusion on Day 1 of each 21-day cycle
Study NCT04691024 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Exercise
Description: Spinal stabilization exercises
Study NCT04691024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Spinal stabilization exercises
Study NCT05911113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: sensory re-education training
Description: the patients will receive sensory re-education training in the form of texture discrimination training, limb position sense and tactile object recognition
Study NCT05911113 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: traditional treatment
Description: the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
Study NCT05911113 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional treatment
Description: the Patients in this group will receive traditional treatment in the form of proprioception neuromuscular facilitation (PNF) and graduated active and resisted wrist and hand muscle strengthening exercises.
Study NCT04269837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Counseling
Description: Receive sexual health counseling
Study NCT04269837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life Assessment
Description: Ancillary studies
Study NCT04269837 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies
Study NCT06185478 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: MRI scan
Description: MRI scan
Study NCT05446974 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nursing Competency Enhancement Training Program in PTSD Intervention
Description: This program was for nurses who work at the Mental Health Welfare Center and consisted of a workbook, self-learning online education, and workshop. It included a spoken audio track that was accompanied by visual prompts to provide knowledge on traumatic stress and introduce trauma recovery methods. Its online format made it convenient and widely accessible, and allowed for a low-intensity, cost-effective educational program. The program focused on providing self-learning guidelines for nurses to develop their capacity for PTSD intervention.
Study NCT06483841 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parents as Partners
Description: The Parents as Partners program consists of 8 weekly group sessions attended by couples and was developed to strengthen the coparental relationship and promote paternal involvement. After consenting to their participation, couples will be randomly assigned to one of two conditions: intervention group or waitlist-control group. Participants will be assessed before and after the intervention on (co)parental, dyadic and work-family dimensions. Baseline (before intervention), post-test (2 months after baseline) and a follow-up assessment 6 months after the program will be performed. The intervention group will participate in the program, focusing on 5 family domains: Parents as Individuals; Parent-Child Relationships; Couple Relationship; Family of Origin Patterns; Stressors and Supports. Parents in the waitlist-control group will receive the intervention once their participation in the study is finished and if positive outcomes are found.